Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify)
in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main
questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS)
score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to
Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.